Naseema Gangat

3 weeks ago | digitalcommons.library.tmc.edu | Naseema Gangat

AbstractPatients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response.

1 month ago | nature.com | Naseema Gangat |Ayalew Tefferi

Venotoclax schedule in acute myeloid leukemia Acute myeloid leukemia (AML) afflicts older individuals (median age 68 years), the majority of whom are unfit to receive intensive induction chemotherapy.

2 months ago | onlinelibrary.wiley.com | Natasha Szuber |Paola Guglielmelli |Naseema Gangat

1 Introduction Sex has been identified as a key regulator of susceptibility to cancer, response to therapy, disease outcomes, and associated mortality [1]. The mechanisms underpinning sex-biased disparities include distinct genetic profiles [2], hormone patterns [3], immune responses [4], and drug metabolism [5].

2 months ago | onlinelibrary.wiley.com | Naseema Gangat |Ayalew Tefferi

Conflicts of Interest N.G. has served on the Advisory Board for DISC Medicine and Agios. References 1, , , et al., “Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients,” Mayo Clinic Proceedings 90, no. 12 (2015): 1623–1638, https://doi.org/10.1016/j.mayocp.2015.08.022. 2, , , et al., “One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience,” Mayo Clinic Proceedings 87, no. 1 (2012): 25–33.

2 months ago | onclive.com | Andrew Kuykendall |Naseema Gangat |Claire Harrison |Raajit Rampal |Pankit Vachhani

OpinionVideoFebruary 28, 2025Author(s):,Panelists discuss key accomplishments in the myeloproliferative neoplasm (MPN) space, highlighting pivotal developments that have shaped clinical practice, and share their excitement for 2025, including areas primed for significant progress and goals for the coming year. Video content above is prompted by the following:What accomplishments in the MPN space are you most proud of? Which developments stand out as pivotal in shaping clinical practice?